Table 1.
Demographic and clinical characteristics of pancreatic cancer patients by glucose-lowering therapies.
| Antihyperglycemic Medications | |||||||
|---|---|---|---|---|---|---|---|
| Variable | Sulfonylurea | Metformin | Sulfonylurea and Metformin | Metformin and Other Medications | Insulin | Other Medications | p Value |
| Total | 114 | 75 | 155 | 67 | 26 | 17 | |
| Gender | |||||||
| Male | 49 (43.0) | 33 (44.0) | 60 (38.7) | 32 (47.8) | 13 (50.0) | 8 (47.1) | 0.78 |
| Female | 65 (57.0) | 42 (56.0) | 95 (61.3) | 35 (52.2) | 13 (50.0) | 9 (52.9) | |
| Age at diagnosis | |||||||
| <60 | 6 (5.3) | 8 (10.7) | 21 (13.5) | 7 (10.4) | 6 (23.0) | 3 (17.7) | 0.009 |
| 60–69 | 26 (22.8) | 16 (21.3) | 43 (27.7) | 28 (41.8) | 8 (30.8) | 9 (52.9) | |
| 70–79 | 48 (42.1) | 36 (48.0) | 62 (40.0) | 22 (32.8) | 8 (30.8) | 4 (23.5) | |
| 80+ | 34 (29.8) | 15 (20.0) | 29 (18.7) | 10 (14.9) | 4 (15.4) | 1 (5.9) | |
| TNM stage | |||||||
| I | 4 (3.5) | 5 (6.7) | 11 (7.1) | 3 (4.5) | 3 (11.5) | 1 (5.9) | 0.94 |
| II | 16 (14.0) | 12 (16.0) | 26 (16.8) | 15 (22.4) | 4 (15.4) | 5 (29.4) | |
| III | 17 (14.9) | 13 (17.3) | 21 (13.5) | 10 (14.9) | 2 (7.7) | 3 17.6) | |
| IV | 61 (53.6) | 33 (44.0) | 72 (46.5) | 28 (41.8) | 14 (53.9) | 7 (41.2) | |
| Missing | 16 (14.0) | 12 (160) | 25 (16.1) | 11 (16.4) | 3 (11.5) | 1 (5.9) | |
| Histology | |||||||
| Adenocarcinoma | 49 (43.0) | 43 (57.3) | 86 (55.5) | 42 (62.7) | 13 (50.0) | 12 (70.6) | 0.17 |
| Other | 12 (10.5) | 3 (4.0) | 6 (3.9) | 5 (7.5) | 2 (7.7) | 1 (5.9) | |
| Neuroendocrine | 4 (3.5) | 1 (1.3) | 10 (6.4) | 1 (1.5) | 2 (7.7) | 1 (5.9) | |
| Not specified | 49 (43.) | 28 (37.4) | 53 (34.2) | 19 (28.3) | 9 (34.6) | 3 (17.6) | |